Can a patient with plaque psoriasis who has been on guselkumab for one year without clinical improvement be switched to tildrakizumab?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Guselkumab to Tildrakizumab After Treatment Failure

Yes, switching from guselkumab to tildrakizumab is a reasonable and evidence-supported option for patients with plaque psoriasis who have failed to respond after one year of guselkumab treatment.

Rationale for Switching Between IL-23 Inhibitors

Both guselkumab and tildrakizumab are IL-23 p19 inhibitors with similar mechanisms of action—they both selectively block the p19 subunit of IL-23 1. However, primary failure to one biologic does not preclude successful response to another biologic, even within the same drug class 1. The 2019 AAD-NPF guidelines explicitly state that "if clinically needed, all other therapies for psoriasis, including other biologics, may be switched with a different biologic agent with the possibility of improved efficacy, safety, and/or tolerability" 1.

When to Consider the Switch

The guidelines recommend assessing definitive response to IL-23 inhibitors after 12 weeks of continuous therapy 1. Since your patient has been on guselkumab for one year without clinical improvement, this clearly represents primary treatment failure. At this point:

  • Discontinue guselkumab and initiate tildrakizumab
  • No washout period is required between IL-23 inhibitors given their similar safety profiles
  • Consider whether loading doses need to be repeated based on disease severity and time elapsed (if more than 3-4 half-lives have passed since the last guselkumab dose, which has a half-life of 15-18 days) 1, 2

Tildrakizumab Dosing Protocol

Initiate tildrakizumab at the FDA-approved dosing regimen 1:

  • 100 mg subcutaneous injection at Week 0
  • 100 mg at Week 4
  • 100 mg every 12 weeks thereafter

This is an in-office physician-administered injection per FDA labeling.

Expected Outcomes After Switching

Real-world evidence demonstrates that tildrakizumab is effective in patients who have failed previous biologic therapy:

  • In a multicenter Italian study of 51 patients who had failed previous biologics, significant PASI reduction occurred by Week 12 (mean PASI decreased from 19.2 to 3.5), with further improvement at Week 48 (PASI 0.6) 3
  • At Week 52, 87% achieved PASI 75,56.5% achieved PASI 90, and 32.6% achieved PASI 100 in real-world settings 4
  • Long-term data through 148 weeks shows maintained efficacy with favorable safety profiles 5

Comparative Efficacy Considerations

While both drugs target the same pathway, network meta-analysis data suggests comparable efficacy between tildrakizumab, guselkumab, and risankizumab at Week 28 for PASI 75, PASI 90, and PGA 0/1 responses 6. However, individual patient response can vary due to:

  • Differences in antibody structure (tildrakizumab is humanized IgG1κ vs. guselkumab's fully human IgG1λ)
  • Potential development of anti-drug antibodies to guselkumab
  • Individual immunologic variability

Important Caveats

The guidelines acknowledge that "not all switches may result in improvement" 1. However, given the patient's complete lack of response to guselkumab after one year, maintaining the current ineffective therapy offers no benefit while exposing the patient to continued disease burden and potential complications.

Alternative considerations if tildrakizumab also fails:

  • Consider switching to a different mechanism of action (IL-17 inhibitors like secukinumab, ixekizumab, or brodalumab)
  • Consider risankizumab (another IL-23 p19 inhibitor with potentially higher binding affinity)
  • Evaluate for combination therapy with topical agents or methotrexate 1

Safety Profile

Tildrakizumab has demonstrated a favorable safety profile with low rates of discontinuation due to adverse events (1.2-1.7 per 100 patient-years) and low rates of serious infections, malignancies, and major adverse cardiovascular events 5. No new safety signals have emerged in real-world studies 3, 4, 7.

Related Questions

In a patient with moderate-to-severe plaque psoriasis refractory to methotrexate, which biologic is preferred: adalimumab (Humira) or etanercept (Enbrel)?
What biologic agents are appropriate first‑line treatments for an adult with moderate‑to‑severe plaque psoriasis who has failed or cannot tolerate topical therapy, and what screening and monitoring considerations are required?
How does tildrakizumab compare to ustekinumab (Stelara) in the treatment of moderate to severe plaque psoriasis in adults?
Is tildrakizumab (generic) indicated for all types of psoriasis in adults, and what is the recommended injection schedule based on disease severity?
How should Tremfya (guselkumab) be used, dosed, and monitored in patients with moderate-to-severe plaque psoriasis or psoriatic arthritis?
What are the indications and potential complications of mirtazapine 7.5 mg tablets?
Does adding azelaic acid to hydroquinone provide a clinically significant improvement in skin lightening for hyperpigmentation?
How should I treat excoriation under the breast?
Does adding azelaic acid to a triple‑combination therapy (hydroquinone 4 %, tretinoin 0.05 %, and a low‑strength topical corticosteroid) produce a clinically significant improvement in skin lightening?
For a 60-year-old woman with three days of dysuria and suprapubic pain, is prescribing phenazopyridine (brand Pyridium) 200 mg every 8 hours for 2 days and nitrofurantoin 100 mg every 6 hours for 7 days appropriate, or what would be a better treatment?
What oral cefdinir dose is appropriate for an adult who has received 2 g of intravenous ceftriaxone?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.